Topics:

Cancer and Genetics

Cancer and Genetics

As part of our coverage of the 2015 ONS Annual Congress, we discuss genetic testing for cancer patients and the role of oncology nurses.

A recent retrospective study elucidates the correlation between breast cancer subtype and metastasis site, time to relapse, and patient survival.

Numerous genomic tests are available for use in colorectal cancer, with a widely variable evidence base for their effectiveness and cost-effectiveness. In this review, we highlight many of these tests, with a focus on their proposed role, the evidence base to support that role, and the associated costs and risks.

Although genomic testing can improve the cost-effectiveness of a treatment, assessing the cost-effectiveness of genomic testing outside the context of its impact on treatment is not practical.

The identification and characterization of gene signatures, driver events, and pharmacogenomics in molecularly homogeneous subsets of patients is likely to advance effective drug development strategies in colorectal cancer.

The use of tumor genome profiling to identify actionable or targetable mutations in women with breast cancer is not ready for routine use in clinical practice.

This article aims to provide an overview of The Cancer Genome Atlas findings, with a particular focus on their potential biological relevance and therapeutic implications.

Pages

Subscribe to Cancer and Genetics on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.